Filing Details

Accession Number:
0001410442-21-000001
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-06 16:15:15
Reporting Period:
2021-01-04
Accepted Time:
2021-01-06 16:15:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
883984 Icu Medical Inc ICUI Surgical & Medical Instruments & Apparatus (3841) 330022692
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1410442 Vivek Jain 951 Calle Amanecer
San Clemente CA 92673
Chairman And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-04 11,500 $58.79 77,741 No 4 M Direct
Common Stock Disposition 2021-01-04 800 $209.24 76,941 No 4 S Direct
Common Stock Disposition 2021-01-04 700 $210.30 76,241 No 4 S Direct
Common Stock Disposition 2021-01-04 2,500 $211.54 73,741 No 4 S Direct
Common Stock Disposition 2021-01-04 4,759 $212.10 68,982 No 4 S Direct
Common Stock Disposition 2021-01-04 708 $213.45 68,274 No 4 S Direct
Common Stock Disposition 2021-01-04 300 $214.33 67,974 No 4 S Direct
Common Stock Disposition 2021-01-04 1,533 $215.58 66,441 No 4 S Direct
Common Stock Disposition 2021-01-04 200 $216.42 66,241 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-01-04 11,500 $0.00 11,500 $58.79
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
413,366 2018-02-13 2024-02-24 No 4 M Direct
Footnotes
  1. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.65 to $209.61, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.84 to $210.55, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.86 to $211.72, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.89 to $212.87, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.91 to $213.78, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.11 to $214.77, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.29 to $216.72, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  10. Twenty-five percent of the shares shall vest on each of the first, second,third, and fourth anniversaries of the vesting commencement date of February 13, 2014. Fifty percent of the vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and twenty-five percent of the exercise price per share for thirty consecutive trading days. The remaining fifty percent of the vested shares shall become exercisable if, after the date of award and on or before the expiration date, the closing price of the Company's common stock is equal to or more than one-hundred and fifty percent of the exercise price for 30 consecutive trading days.